- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925610
Recovery of Ventilation After General Anesthesia in Morbidly Obese Patients
Recovery of Ventilation After General Anesthesia in Morbidly Obese Patients Who Are Treated With Opioids: A Preliminary Investigation
Study Overview
Status
Detailed Description
Obstructive sleep apnea (OSA) increases the risk for pulmonary complications in the first 24 hours after surgery, by more than 3-fold, suggesting an enhanced sensitivity to opioid-induced ventilatory depression (OIVD), in this patient population. Obesity and OSA, two highly comorbid conditions, are common among victims of postoperative life-threatening or fatal OIVD and increased somnolence preceding the onset of a critical event, is an almost ubiquitous clinical finding.
These clinical observations are in agreement with recent evidence that decreased wakefulness is an important contributory mechanism of OIVD in OSA patients who receive opioid analgesia in the postoperative period. Studies that examined the effect of opioids on breathing in awake, sleeping, or anesthetized patients with OSA, support overall that OSA is not associated with increased sensitivity to OIVD in awake subjects. In contrast, diminished wakefulness has been shown to worsen, leave unaffected, or even slightly improve breathing and oxygenation in patients with OSA, who are treated opioids.
Decrease in the tonic activity of the pharyngeal muscles with the progression from wakefulness to sleep, contributes to increased airway resistance and the predisposition to airway occlusion. This effect of sleep on the patency of pharyngeal airway seems to be more pronounced in patients with OSA, who present with increased genioglossus muscle activity during wakefulness taken as evidence for a neural compensation to maintain adequate airflow in the presence of anatomical airway narrowing.
It can thus be suggested that during pharmacological suppression of consciousness, like when recovering from anesthesia, patients with OSA will experience more severe sleep-disordered breathing and consequently be more vulnerable to OIVD, compared to normal subjects.
Specific Aims
Specific Aim 1: To assess opioid-induced ventilatory depression in morbidly obese patients with OSA, who recover from general anesthesia and are treated for pain with fentanyl. We will develop a pharmacodynamic model for OIVD to assess the effect of OSA status (i.e., moderate-to-severe OSA vs. no or mild OSA) on the probability for TcPCO2 to exceed a pre-specified threshold during recovery from anesthesia.
Specific Aim 2: To assess the effect of baseline TcPCO2 on the probability for TcPCO2 to exceed a pre-specified threshold during recovery from anesthesia, independently of the OSA status.
Specific Aim 3: To assess the effect of the minimum positive airway pressure (minPAP) that prevents obstructive breathing during sleep (estimated during in-lab polysomnography) on the probability for TcPCO2 to exceed a pre-specified threshold, during recovery from anesthesia.
Hypotheses:
- Patients with moderate-to-severe OSA will demonstrate a higher probability for exceeding a pre-specified threshold for TcPCO2, compared to those with mild or no OSA, during recovery from general anesthesia.
- Patients who present with higher TcPCO2 at baseline, will present with a higher probability to exceed a pre-specified threshold for TcPCO2, independently of their OSA status, compared to those with normal ventilatory control at baseline, during recovery from anesthesia.
- Patients with higher therapeutic PAP level (hence more collapsible airway) will be more sensitive to fentanyl-induced ventilatory depression and will thus demonstrate a higher probability for exceeding a pre-specified threshold for TcPCO2 during recovery from anesthesia.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Body mass index (BMI) equal or greater than 35 kg/m2.
- American Society of Anesthesiologists (ASA) physical status I - III patients.
- Scheduled to undergo laparoscopic roux-en-Y gastric bypass or gastric sleeve placement surgery for weight loss.
Exclusion Criteria:
- Chronic obstructive pulmonary disorder (COPD).
- Treatment with continuous positive airway pressure (CPAP) in the past three months.
- Severe neurological, cardiopulmonary, psychiatric, or untreated thyroid disorder.
- Chronic pain condition that was being treated with opioids.
- Patients with a hematocrit lower than 35%.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Morbidly obese patients with moderate-to-severe OSA
Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery. All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring. Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3). A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2. |
Morbidly obese patients with no or mild OSA
Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery. All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring. Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3). A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Probability for TcPCO2 / PaCO2 to exceed a pre-specified threshold during recovery from anesthesia.
Time Frame: PACU period (approximate duration of about 1.5h).
|
Probability for TcPCO2 / PaCO2 to exceed a pre-specified threshold during recovery from anesthesia.
|
PACU period (approximate duration of about 1.5h).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of baseline ventilation on the primary outcome
Time Frame: PACU period (approximate duration of about 1.5h)
|
Effect of baseline ventilation, expressed as transcutaneous and arterial PCO2, on the primary outcome.
|
PACU period (approximate duration of about 1.5h)
|
The effect of the minimum PAP on the primary outcome.
Time Frame: PACU period (approximate duration of 1.5h)
|
The effect of the minimum positive airway pressure (minPAP) that prevents obstructive breathing during sleep (estimated during in-lab polysomnography) on the probability for TcPCO2 /PaCO2 to exceed a pre-specified threshold
|
PACU period (approximate duration of 1.5h)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anthony Doufas, MD, PhD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Nervous System Diseases
- Substance-Related Disorders
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Narcotic-Related Disorders
- Obesity
- Sleep Apnea Syndromes
- Opioid-Related Disorders
- Obesity, Morbid
Other Study ID Numbers
- IRB-49407
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea Syndromes
-
Tampere University HospitalActive, not recruiting
-
Sheffield Children's NHS Foundation TrustCompletedSleep Apnea Syndromes in ChildrenUnited Kingdom
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
University Hospital, GrenobleIcadom; DOCAPOST; SunriseCompletedSleep Apnea Syndrome, ObstructiveFrance
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
-
Hillel Yaffe Medical CenterUnknownSleep Apnea Syndromes, ObstructiveIsrael
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
Democritus University of ThraceRecruitingConcentration Ability Impaired | Sleep Apnea Syndrome, Obstructive | Blinking | Pupil Diameter | DrowsinessGreece
-
Poitiers University HospitalCompletedObstructive Sleep Apnea Syndromes